PreciseDx has shared an update. The company announced that three scientific presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2025 will feature new data on PreciseBreast, its AI-powered digital pathology test designed to assess breast cancer risk of recurrence. The accepted abstracts cover an AI-based prognostic test using biopsy specimens, an AI-enabled phenotyping approach for triple negative breast cancer, and a real-world evaluation of PreciseBreast for early-stage invasive breast cancer risk stratification in collaboration with Lankenau Medical Center/Main Line Health.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
For investors, the inclusion of multiple PreciseBreast-focused studies at a major oncology conference signals growing clinical interest and potential validation of the company’s technology. Positive or robust data outcomes could strengthen the clinical utility case for PreciseBreast, supporting future adoption by healthcare providers and payers. Demonstrated effectiveness in real-world settings and across specific subtypes such as triple negative breast cancer may enhance the company’s competitive positioning within the AI-driven diagnostics and digital pathology market. While no commercial or revenue figures were disclosed, broader recognition at SABCS could lay the groundwork for future partnerships, reimbursement discussions, and market expansion, all of which may influence the company’s long-term growth prospects.